Page 766 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

750 Index

Hemoglobin (Continued) physical agents, 300–301 Hereditary hemochromatosis (HH), 258, 270–271
analysis trans usion reactions, 303–304 classi cation and characteristics, 270–271

alkaline electrophoresis, 130, 130 complement, role o pathophysiology and laboratory characteristics,
chromatography, 131 activation pathways, 293, 293–294 271
citrate agar electrophoresis, 131 alternative pathway, 295 treatment, 271
cyanmethemoglobin method, 130 atypical hemolytic uremic syndrome Hereditary hydrocytosis, 298, 298

denaturation procedure, 131, 131 (aHUS), 294 Hereditary pyropoikilocytosis (HPP), 297
hemoglobincyanide, 130 classic complement pathway, 294 Hereditary spherocytosis (HS), 296, 296
molecular testing, 131 mannose-binding lectin pathway, 295 Hereditary stomatocytosis, 298, 298
biosynthesis membrane disruption, 295 Hereditary storage pool de ect, 521, 521t

globin structure and synthesis, 125–126 paroxysmal nocturnal hemoglobinuria (PN Hereditary xerocytosis, 297–298
globin synthesis, 272 H), 294 Heterochromatin, 63–64
heme synthesis, 123, 126, 127 regulatory proteins, 294b HFE protein, 124–125
hepcidin, 124, 265–267 diagnostic tests, 305–306 High iron Fe (HFE-gene), 270–271

iron, role o , 123–125 hemolysis, 295t High molecular weight kininogen de ciency
porphyrin, 271–272 inherited (HMWK) de ciency, 559
carbon dioxide transport, 122–123 acanthocytosis, 298, 298–299 Highpressure liquid chromatography (HPLC), 131
chemical composition, 120 erythrocytic enzyme de ects, 299 Histiocytes, 169

con guration, 120 etiology, 295 Histogram, 619
genetic hemoglobin abnormalities, 122 glucose-6-phosphate dehydrogenase Histones, 63, 64
genetic inheritance, 120 (G6PD), 299–300 HIV (see Human immunode ciency virus)
heme pigment, 105 hemoglobin molecule de ects, 295b Hodgkin disease

heme portion, 121 hereditary elliptocytosis (HE), 297 cytogenetic analysis, 434
ontogeny hereditary hydrocytosis, 298, 298 epidemiology, 432
embryonic, 128 hereditary pyropoikilocytosis (HPP), 297 etiology, 432
etal, 128 hereditary spherocytosis (HS), 296, 296 laboratory ndings, 432–433, 433

glycosylated/hemoglobin A1, 128–129 hereditary stomatocytosis, 298, 298 prognosis, 433
hemoglobin A, 128 hereditary xerocytosis, 297–298 prognostic actors, 434
oxygen alterations, 122 neuroacanthocytosis (NA), 299 treatment, 434
oxygen dissociation, 121–122 Rh disease, 298 Homeostatic proli eration, 191
null
structure, 120, 120 spur cell hemolytic anemia, 299 Horiba ABX Diagnostics, Inc., 625
variant orms structural membrane de ects, 295–296 Howell–Jolly bodies, 115, 132, 150, 151, 152
carboxyhemoglobin, 129 pathophysiology, 304–305 H LV (see Human -cell leukemia viruses)
methemoglobin, 129 Hemolytic disease o the etus and newborn Human Genome Project

sul emoglobin, 129 (HDFN), 205–206, 302–303 gene rearrangement studies, 654
Hemoglobin C disease, 327, 327 Hemolytic trans usion reactions, 303–304 hematopathology, 654
Hemoglobin D disease, 327 Hemolytic-uremic syndrome (HUS), 517–518 minimal residual disease, 654
Hemoglobin de ects Hemopexin, 133 Human granulocytic ehrlichiosis (HGE), 342

demographics, 314, 314b Hemophilia A Human immunode ciency virus (HIV)
etiology epidemiology, 551 isolation, 4
abnormal hemoglobin, 315, 315b etiology, 551, 552 nosocomial transmission, 5
disease vs. trait, 315 laboratory ndings, 552 occupational exposure

etal hemoglobin, 328 pathophysiology, 551–552 blood-borne virus postexposure issues, 5
normal vs. sickle hemoglobin molecules, 314 signs and symptoms, 551 pathogens, 3
structure, 314 Hemophilia B (christmas disease) sharps prevention, 5
Hemoglobin E disease, 327–328 epidemiology, 552 sequence, 660

Hemoglobin electrophoresis, cellulose acetate etiology, 552 Human stem cells (HSCs)
method, 681–683, 682 laboratory ndings, 553 bone cells, 92
Hemoglobin F determination, 689, 689 signs and symptoms, 552–553 erythropoiesis, 91
by acid elution, 515, 515 Hemosiderin, 63 granulopoiesis, 91

Hemoglobin H disease, 328 Hemosiderinuria, 133 lymphopoiesis, 91
Hemoglobin (Hb) measurement, 211 Hemostasis, 545 macrophages, 91–92
Hemoglobin molecule de ects, 295b platelet unction (see Platelets) marrow stromal cells, 91
Hemoglobin S (Hb S) screening test, 683 processes, 490 mast cells, 91

Hemoglobin SC disease, 322, 327 Henoch-Schonlein purpura (HSP), 506 megakaryopoiesis, 91
Hemoglobincyanide, 130 Heparin, 28 progenitor blood cells, 90–91
Hemoglobinemia, 133 in vitro anticoagulant, 28 Human -cell leukemia viruses (H LV), 376
Hemoglobinopathies, 120 (see also Hemoglobin in vivo anticoagulant, 28 Hydrophilic regions, 60

de ects) Heparin-induced thrombocytopenia (HI ), Hypercellular bone marrow, 450
Hemoglobinuria, 305 510–512, 511 Hypercoagulable state, 563, 566t
Hemolytic accelerated red cell destruction, 233 Hepatitis-associated aplastic anemia, 245 antiphospholipid antibodies, 568–569
Hemolytic anemias Hepatitis B virus (HBV) antiphospholipid syndrome, 569–570

acquired blood-borne virus postexposure issues, 5 antithrombin III de ciency
autoimmune hemolytic anemias (AIHA), HBe antigen, 4 decreased A -III levels, acquired, 573
301–302 nosocomial transmission, 5 decreased A -III levels, congenital, 573
chemicals and venoms, 300 occupational exposure heparin co actor de ciency, 573

delayed reaction, 304 pathogens, 3 arterial and venous thrombosis, 563, 565
drug-induced immune hemolytic anemia sharps prevention, 5 blood clotting actors, 566–567
(DIIHA), 304 vaccination, 5 circulating inhibitors, 567–568
etiology, 300, 301b Hepatosplenomegaly, 84 actor II, VII, IX, and X inhibitors, 568

immune mechanisms, 301 Hepcidin, 124, 265–267 actor IX inhibitor, 568
in ectious microorganisms, 301, 302t Hereditary, 325 actor V inhibitor, 568
isoimmune hemolytic anemia, 302–303 Hereditary clotting de ects, 553–556, 553t, 554t, actor VIII inhibitor, 568
medical conditions, 304 556t actor XI and XII inhibitors, 568

medication, 304 Hereditary elliptocytosis (HE), 297, 297 brinogen, brin, and actor XIII inhibitors,
microangiopathic red cell destruction, 301 Hereditary/ amilial thrombocytosis, 515–516 568